AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Go back to AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients| AbbVie (NYSE: ABBV) | Delayed: 264.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.02 | 52 Week High | $68.12 | |||
| Open | $264.02 | 52 Week Low | $50.71 | |||
| Day High | $264.02 | P/E | 57.27 | |||
| Day Low | $264.02 | EPS | $4.61 | |||
| Volume | 663 | |||||
